Literature DB >> 16985154

Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.

James M Provenzale1, Gerald York, Marcelo Galvez Moya, Lauren Parks, Michael Choma, Susan Kealey, Patricia Cole, Humaira Serajuddin.   

Abstract

OBJECTIVE: The purpose of this study was to correlate the degree of contrast enhancement on dynamic contrast-enhanced T1-weighted MRI and the relative cerebral blood volume (rCBV) values on T2*-weighted MRI in patients with high-grade brain neoplasms. SUBJECTS AND METHODS: Ten patients with biopsy-proven high-grade gliomas underwent dynamic contrast-enhanced MRI using T1-weighted fast spoiled gradient-echo technique (TR/TE, 8.3/1.5) during i.v. infusion of 0.1 mmol/kg of MR contrast medium. This sequence was followed within 5 minutes by dynamic susceptibility contrast (DSC) imaging (1,500/80) during i.v. infusion of 0.2 mmol/kg of MR contrast medium. Dynamic contrast-enhanced analysis was performed using the maximum-signal-intensity algorithm, and DSC analysis was performed using the negative enhancement integral program. For each tumor, we performed two comparisons: first, the average dynamic contrast-enhanced and rCBV values within a region of interest drawn around the entire contrast-enhancing tumor on a single image through the center of the lesion and, second, the highest dynamic contrast-enhanced and highest rCBV values within each tumor. Statistical analyses of the first comparison were performed using Pearson's correlation coefficient, R2 correlation coefficient, and Spearman's rank correlation and for the second comparison using Kendall's tau correlation.
RESULTS: The mean signal intensity values ranged between 3.48 and 7.16 SDs above baseline values (mean, 4.89 SDs). The mean rCBV values ranged between 57.9% and 122.7% of the normal lentiform nucleus (mean, 76.6%). The Pearson's correlation coefficient was 0.867, the R2 correlation coefficient was 0.752, and the Spearman's rank correlation was 0.794 (p = 0.001). Dynamic contrast-enhanced values from the region of highest signal intensity ranged between 7.7 and 48.6 SDs above baseline values (mean, 17.3 SDs). The highest rCBV values ranged between 105% and 400% of the normal lentiform nucleus (mean, 292%). The correlation was estimated to be 0.7778 and was statistically significant at the 0.01 level of statistical significance (p = 0.0035).
CONCLUSION: We found a high correlation between degree of contrast enhancement on dynamic contrast-enhanced images and rCBV values in whole tumors and in regions having the highest degree of contrast enhancement in this small study. Our findings, which suggest that relative permeability and rCBV values may be correlated in high-grade glial neoplasms, deserve further study in a larger patient population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16985154     DOI: 10.2214/AJR.04.0676

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas.

Authors:  Na Zhang; Lijuan Zhang; Bensheng Qiu; Li Meng; Xiaoyi Wang; Bob L Hou
Journal:  J Magn Reson Imaging       Date:  2012-05-11       Impact factor: 4.813

2.  Incorporating a vascular term into a reference region model for the analysis of DCE-MRI data: a simulation study.

Authors:  A Z Faranesh; T E Yankeelov
Journal:  Phys Med Biol       Date:  2008-04-25       Impact factor: 3.609

3.  Pixel-by-Pixel Comparison of Volume Transfer Constant and Estimates of Cerebral Blood Volume from Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast-Enhanced MR Imaging in High-Grade Gliomas.

Authors:  P Alcaide-Leon; D Pareto; E Martinez-Saez; C Auger; A Bharatha; A Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2015-01-29       Impact factor: 3.825

4.  Comparison between CT and MR in perfusion imaging assessment of high-grade gliomas.

Authors:  M De Simone; C F Muccio; S M Pagnotta; G Esposito; A Cianfoni
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

5.  Glioma: Application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading.

Authors:  S C Jung; J A Yeom; J-H Kim; I Ryoo; S C Kim; H Shin; A L Lee; T J Yun; C-K Park; C-H Sohn; S-H Park; S H Choi
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-02       Impact factor: 3.825

Review 6.  Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma.

Authors:  Ali S Arbab
Journal:  Histol Histopathol       Date:  2012-05       Impact factor: 2.303

7.  Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma.

Authors:  Roberto Sanz-Requena; Antonio J Revert-Ventura; Gracián García-Martí; Fares Salamé-Gamarra; Alexandre Pérez-Girbés; Enrique Mollá-Olmos; Luis Martí-Bonmatí
Journal:  Eur Radiol       Date:  2016-12-20       Impact factor: 5.315

8.  High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging.

Authors:  Italo Aprile; Giorgia Giovannelli; Paola Fiaschini; Marco Muti; Anna Kouleridou; Nevia Caputo
Journal:  Radiol Med       Date:  2015-03-12       Impact factor: 3.469

9.  Establishment and results of a magnetic resonance quality assurance program for the pediatric brain tumor consortium.

Authors:  Robert V Mulkern; Peter Forbes; Kevin Dewey; Stravoula Osganian; Maureen Clark; Sharon Wong; Uma Ramamurthy; Larry Kun; Tina Young Poussaint
Journal:  Acad Radiol       Date:  2008-09       Impact factor: 3.173

10.  Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence.

Authors:  Friso W A Hoefnagels; Frank J Lagerwaard; Esther Sanchez; Cornelis J A Haasbeek; Dirk L Knol; Ben J Slotman; W Peter Vandertop
Journal:  J Neurol       Date:  2009-03-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.